Furthermore, immune classification based on NSD2 expression and CD4+ TILs and CD8+ TILs was used to stratify prostate cancer patients based on prostate-specific antigen overall survival and showed that increased NSD2 expression was predictive of reduced overall survival. The gene discussed is CD4; the disease is prostate carcinoma.